---
title: "JOINN's annual net profit is 298 million RMB, a threefold increase, with a final dividend of 12 cents"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281071009.md"
description: "JOINN announced its 2025 annual performance, with revenue of 1.658 billion RMB (same below), a year-on-year decrease of 17.9%. It recorded a net profit of 298 million RMB, an increase of 302.1%, with earnings per share of 0.40 RMB. The final dividend is 0.12 RMB, compared to 0.03 RMB in the same period last year"
datetime: "2026-03-30T20:05:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281071009.md)
  - [en](https://longbridge.com/en/news/281071009.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281071009.md)
---

# JOINN's annual net profit is 298 million RMB, a threefold increase, with a final dividend of 12 cents

JOINN (06127.HK) announced its 2025 annual performance, with revenue of 1.658 billion RMB, a year-on-year decrease of 17.9%. It recorded a net profit of 298 million RMB, an increase of 302.1%, with earnings per share of 0.40 RMB. The final dividend is 0.12 RMB, compared to 0.03 RMB in the same period last year

### Related Stocks

- [06127.HK](https://longbridge.com/en/quote/06127.HK.md)
- [516930.CN](https://longbridge.com/en/quote/516930.CN.md)
- [603127.CN](https://longbridge.com/en/quote/603127.CN.md)
- [159849.CN](https://longbridge.com/en/quote/159849.CN.md)
- [159837.CN](https://longbridge.com/en/quote/159837.CN.md)
- [516500.CN](https://longbridge.com/en/quote/516500.CN.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [JOINN Laboratories Grants New Three-Year H-Share Awards to Management](https://longbridge.com/en/news/284780987.md)
- [FendX Engages Innovotech for Regulatory Pathway Assessment of Its Coated Foley Catheter Program | FDXTF Stock News](https://longbridge.com/en/news/284651899.md)
- [GenFleet Asserts Independent IP for Pan RAS Inhibitor GFH276 Amid Sector Dispute](https://longbridge.com/en/news/284312081.md)
- [ZAWYA: Emirates Drug Establishment approves first nasal epinephrine spray as alternative to injections for severe allergic reaction](https://longbridge.com/en/news/284603051.md)
- [CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026](https://longbridge.com/en/news/284213122.md)